In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Prevalence of adverse pronostic factors in pulmonary hypertension

Session Poster Session 1

Speaker Adrian Lescano

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Poster Session
  • FP Number : P528

Authors : A Lescano (BUENOS AIRES,AR), A Rossi (BUENOS AIRES,AR), G Sorasio (BUENOS AIRES,AR), E Besmalinovich (BUENOS AIRES,AR), R Caprini (BUENOS AIRES,AR), C Musante (BUENOS AIRES,AR), M Vergara (BUENOS AIRES,AR), C Miranda (BUENOS AIRES,AR), J Farina (BUENOS AIRES,AR), R Skena (BUENOS AIRES,AR), GD G Dionisio (BUENOS AIRES,AR)

Authors:
A Lescano1 , A Rossi1 , G Sorasio1 , E Besmalinovich1 , R Caprini1 , C Musante1 , M Vergara1 , C Miranda1 , J Farina1 , R Skena1 , GD G Dionisio1 , 1QUILMES TRINIDAD CLINIC - BUENOS AIRES - Argentina ,

Citation:

Pulmonary hypertension (PH) is a multi-factorial condition associated with high morbidity and mortality. This requires for its diagnosis and treatment a multidisciplinary approach. There have been many advances in the epidemiological, pathophysiological and therapeutic knowledge of the disease in the past decades. However, there is little information available regarding clinical and prognostic factors in patients diagnosed with PH in Latin America. 

Purpose: Determine the prevalence and clinical characteristics of adverse prognostic factors in a population with recent diagnosis of PH.  
Methods:  Patients with recent diagnosis of PH (< 7 days), confirmed by right heart catheterization, with a mean pulmonary-artery pressure (MPAP) = 25 mm Hg (using a Swan Ganz Catheter) from three heart failure and pulmonary hypertension services were analyzed between March 2012 and December 2018. According to the recommendations of international guidelines, the following data were recorded: Personal data; PH group (G); clinical features: symptoms, functional class (FC); Direct hemodynamic parameters: pulmonary pressures (PP), wedge pressure (WP), right atrium pressure (RA) and cardiac index (CI); Functional: 6 minute walk (6MW) test distance; Echocardiographic variables: right ventricle systolic function (RVSF), systolic pulmonary pressure and presence of pericardial effusion (PE).  Data obtained weas analyzed with STATA 14 program. Adverse prognosis factors identified were: history of heart failure (HF), syncope, advance functional class (III-IV), performance in the 6MW test < 440 m, presence of PE, RA = 14 mm Hg e CI = 2,2 litres/min/mt2 

Results:  Multicenter, observational, descriptive, consecutive and prospective study. 148 patients were included, from which 75% were women. Mean age was 57.8 (±19) years, 27% = 70. The mean delay in diagnosis was 23 months after the first sign or symptom recorded. PH group distribution: GI 68%, GII 13%, GIII 7%, GIV 6% and GV 6%. FC of presentation: I 4%, II 39%, III 36% and IV 21%. History of HF in 79%, syncope in 24%. 6MW mean walked distance was 317 (±144) meters, 74% performed = 440 meters. RHC: MPAP 48 (±16) mm Hg, RAP 9 mm HG (±5) and = 14 mm Hg 19 %; CI 2,8 litres/min/mt2 (= 2,2 22%). Ecocardiographic data showed: 80 % impaired FSVD (40% slight, 19% moderate and 21% severe) and PE in 25%.

Conclusions: In our population with confirmed pulmonary hypertension, with a group I predominance, we had a high prevalence of presentation in patients over 70 years of age. At diagnosis time a high number of patients presented adverse prognosis factors. These findings remark the need of using early diagnosis and therapeutic strategies.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are